Values First Advisors Inc. Acquires 1,538 Shares of Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 5.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,597 shares of the company’s stock after acquiring an additional 1,538 shares during the quarter. Values First Advisors Inc.’s holdings in Guardant Health were worth $1,263,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in Guardant Health in the fourth quarter worth $43,000. Kimelman & Baird LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth $58,000. NewEdge Advisors LLC increased its stake in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after buying an additional 230 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health in the 4th quarter valued at $61,000. Finally, GF Fund Management CO. LTD. acquired a new stake in Guardant Health in the 4th quarter valued at $79,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Price Performance

GH stock opened at $49.54 on Tuesday. The company has a 50 day simple moving average of $45.48 and a 200 day simple moving average of $43.32. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of -14.61 and a beta of 1.44. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $53.42.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same period in the previous year, the firm earned ($0.46) earnings per share. The company’s revenue was up 20.8% compared to the same quarter last year. On average, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 3,213 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total transaction of $158,947.11. Following the transaction, the director directly owned 7,190 shares of the company’s stock, valued at $355,689.30. This represents a 30.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the transaction, the chief executive officer directly owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. This represents a 4.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 342,274 shares of company stock valued at $17,080,589 over the last 90 days. 6.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GH has been the subject of a number of analyst reports. Canaccord Genuity Group lifted their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. UBS Group lifted their target price on shares of Guardant Health from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, May 1st. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Scotiabank reaffirmed an “outperform” rating on shares of Guardant Health in a report on Monday, May 5th. Finally, Stephens reaffirmed an “overweight” rating and set a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Twenty-one investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and a consensus target price of $53.76.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.